Literature DB >> 8225526

Arterial smooth muscle cell phenotype in stroke-prone spontaneously hypertensive rats.

F Contard1, A Sabri, M Glukhova, S Sartore, F Marotte, J P Pomies, P Schiavi, D Guez, J L Samuel, L Rappaport.   

Abstract

The aim of this study was to determine the phenotype of smooth muscle cells in the arteries of chronically hypertensive animals and to analyze the effects of treatments known to increase the survival of the animal without a clear effect on its hypertensive state. Stroke-prone spontaneously hypertensive rats (SHRSP) kept on a 1% sodium drinking solution were untreated or treated with one of two diuretics, indapamide (3 mg/kg per day) or hydrochlorothiazide (20 mg/kg per day), from 6 to 13 weeks of age. Phenotype was characterized by the immunolabeling of arteries with antibodies raised against a cellular form (EIIIA) of fibronectin, alpha-smooth muscle actin, and nonmuscle myosin. We demonstrated that phenotypes of smooth muscle cells of the SHRSP differ from those found in Wistar-Kyoto rats. The difference in phenotype is specific for the vessel type: ie, an increased expression of nonmuscle myosin in the aorta and of both EIIIA fibronectin and nonmuscle myosin in the coronary arteries. The two diuretics (1) had no effect on blood pressure, (2) prevented or did not prevent the increase in medial thickness, and (3) prevented changes in both smooth muscle cell phenotype and ischemic tissular lesions. Taken together, the results suggest that in SHRSP the changes in the phenotype of smooth muscle cells and the thickness of arteries are unrelated events. We propose that the maintenance of the contractile phenotype of the arterial smooth muscle cells could be an essential parameter involved in the prevention of the deleterious consequences characteristic of a severe hypertensive state.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8225526     DOI: 10.1161/01.hyp.22.5.665

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension.

Authors:  C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

Review 2.  Pharmacological properties of indapamide. Rationale for use in hypertension.

Authors:  A Bataillard; P Schiavi; J Sassard
Journal:  Clin Pharmacokinet       Date:  1999       Impact factor: 6.447

Review 3.  Extracellular matrix and growth factors during heart growth.

Authors:  S Corda; J L Samuel; L Rappaport
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

4.  The salted artery and angiotensin II signaling: a deadly duo in arterial disease.

Authors:  Mingyi Wang; Edward G Lakatta
Journal:  J Hypertens       Date:  2009-01       Impact factor: 4.844

Review 5.  Redox signaling, vascular function, and hypertension.

Authors:  Moo Yeol Lee; Kathy K Griendling
Journal:  Antioxid Redox Signal       Date:  2008-06       Impact factor: 8.401

Review 6.  Neural Vascular Mechanism for the Cerebral Blood Flow Autoregulation after Hemorrhagic Stroke.

Authors:  Ming Xiao; Qiang Li; Hua Feng; Le Zhang; Yujie Chen
Journal:  Neural Plast       Date:  2017-09-26       Impact factor: 3.599

Review 7.  Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction.

Authors:  Domenico D'Amario; Stefano Migliaro; Josip A Borovac; Attilio Restivo; Rocco Vergallo; Mattia Galli; Antonio Maria Leone; Rocco A Montone; Giampaolo Niccoli; Nadia Aspromonte; Filippo Crea
Journal:  Front Physiol       Date:  2019-11-05       Impact factor: 4.566

8.  The vasculature in HFpEF vs HFrEF: differences in contractile protein expression produce distinct phenotypes.

Authors:  Melissa A Lyle; Mohamad S Alabdaljabar; Young Soo Han; Frank V Brozovich
Journal:  Heliyon       Date:  2019-12-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.